Melanoma cells with JAK1/2 deletion are resistant to IFN-induced anticancer activity, whereas melanoma cells with B2M loss block melanoma cells from being recognized by antigen-specific T cells and maybe therefore resistant to cytotoxicity. This evidence concerns the gene JAK1 and melanoma.